2017
Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.
ŠPUNAROVÁ, Michaela, Jitka MALČÍKOVÁ, Nikola TOM, Marek BORSKÝ, Yvona BRYCHTOVÁ et. al.Basic information
Original name
Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.
Authors
ŠPUNAROVÁ, Michaela (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Anna PANOVSKÁ (203 Czech Republic, belonging to the institution), Eva DIVÍŠKOVÁ (203 Czech Republic, belonging to the institution), Marek MRÁZ (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Martin TRBUŠEK (203 Czech Republic, belonging to the institution)
Edition
22nd congress of EHA, Madrid, Španělsko, červen 2017 in Haematologica (2017), 2017
Other information
Language
English
Type of outcome
Conference abstract
Field of Study
10606 Microbiology
Confidentiality degree
is not subject to a state or trade secret
RIV identification code
RIV/00216224:14110/17:00099492
Organization unit
Faculty of Medicine
Keywords in English
recurrent mutations; CLL; impact
Changed: 9/2/2018 21:18, Bc. Kateřina Kolesová
Abstract
V originále
Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens. Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.
Links
| MUNI/A/1106/2016, interní kód MU |
| ||
| 16-32743A, interní kód MU (CEP code: NV16-32743A) |
|